ERBB2 and gastric cancer: In the present work, we developed a preclinical model using human HER2-positive gastric cancer cells in order to assess the activity of trastuzumab in combination with the AKT-inhibitor ipatasertib or the anti-HER3 antibody duligotuzumab.